Synonym
AJ 3941, AJ-3941, AJ3941
IUPAC/Chemical Name
Piperazine, 1-(3-fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)-, (E)-(+-)-, (Z)-2-butenedioate (1:2)
InChi Key
BGBBGKWUEFWPAV-PBCGGMKNSA-N
InChi Code
1S/C27H27FN2O.2C4H4O4/c28-23-12-13-25-26(19-23)31-20-22-10-4-5-11-24(22)27(25)30-17-15-29(16-18-30)14-6-9-21-7-2-1-3-8-21;2*5-3(6)1-2-4(7)8/h1-13,19,27H,14-18,20H2;2*1-2H,(H,5,6)(H,7,8)/b9-6+;2*2-1+
SMILES Code
C(\C=C\C(=O)O)(=O)O.N1(CCN(CC1)C\C=C\c1ccccc1)[C@@H]1c2c(OCc3c1cccc3)cc(cc2)F.C(\C=C\C(O)=O)(=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
646.67
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Minato H, Hashizume M, Masuda Y, Fujitani B, Hosoki K. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog. Arzneimittelforschung. 1997 Apr;47(4):339-46. PubMed PMID: 9150852.
2: Minato H, Honda Y, Masuda Y, Fujitani B, Hosoki K. Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303. PubMed PMID: 8982668.
3: Minato H, Honda Y, Masuda Y, Fujitani B, Hosoki K. Protective effect of the novel cerebrovascular-selective calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]-oxepine-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate on ischemic brain damage after permanent middle cerebral artery occlusion in rats. Arzneimittelforschung. 1996 Jun;46(6):567-71. PubMed PMID: 8767345.
4: Kurono M, Yoshida K, Naruto S. Determination of AJ-3941, a possible agent for the treatment of cerebrovascular disorders, in plasma and brain by means of high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1992 Jul 1;578(1):152-6. PubMed PMID: 1400782.
5: Kurokawa M, Sato F, Masuda Y, Yoshida T, Ochi Y, Zushi K, Fujiwara I, Naruto S, Uno H, Matsumoto J. Synthesis and biological activity of 11-[4-(cinnamyl)-1-piperazinyl]- 6,11-dihydrodibenz[b,e]oxepin derivatives, potential agents for the treatment of cerebrovascular disorders. Chem Pharm Bull (Tokyo). 1991 Oct;39(10):2564-73. PubMed PMID: 1806275.
